Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of
autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor in
patients with relapsed or refractory B-Cell Non-Hodgkin Lymphoma.